BioCryst Pharmaceuticals, Inc.BCRXNASDAQ
Loading
Operating Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+7.6%
5Y CAGR+21.9%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
+7.6%/yr
vs +37.8%/yr prior
5Y CAGR
+21.9%/yr
Recent deceleration
Acceleration
-30.2pp
Decelerating
Percentile
P100
Near historical high
vs 5Y Ago
2.7x
Strong expansion
Streak
9 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| TTM | $514.44M | +16.7% |
| 2024 | $440.77M | +2.4% |
| 2023 | $430.46M | +4.3% |
| 2022 | $412.67M | +26.0% |
| 2021 | $327.63M | +71.6% |
| 2020 | $190.89M | +32.4% |
| 2019 | $144.19M | +26.0% |
| 2018 | $114.40M | +41.4% |
| 2017 | $80.89M | +11.9% |
| 2016 | $72.26M | - |